Regulatory News In Brief
FDA begins releasing summary review memos for 180-day PMA supplements as part of a transparency pilot. Invacare and FDA agree on consent decree terms. More regulatory news.
FDA begins releasing summary review memos for 180-day PMA supplements as part of a transparency pilot. Invacare and FDA agree on consent decree terms. More regulatory news.